



SEQUENCE LISTING

<110> Max-Delbrueck-Centrum fuer Molekulare Medizin

<120> Tumor vaccines for mucl-positive carcinomas

<130> 0107-027

<140> Ser. No. 09/606,910

<141> 2000-06-29

<150> DE 197 58 400.4

<151> 1997-12-30

<150> PCT/DE98/03819

<151> 1998-12-30

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> human

<220>

<223> immunodominant region of MUC1

<400> 1

Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 2

<211> 8

<212> PRT

<213> mouse, IgG1

<220>

<223> A76-A/C7 epitope

<400> 2

Ala Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 3

<211> 6

<212> PRT

<213> mouse, IgG1

<220>

<223> MF06 epitope

<400> 3

Asp Thr Arg Pro Ala Pro
1 5

<210> 4

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: designed
synthetical glycopeptide

<400> 4

Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser
1 5 10 15

Thr Ala Pro Pro Ala
20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: designed
synthetical glycopeptide

<400> 5

His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr
1 5 10 15

Ala Pro Pro Ala
20

<210> 6

<211> 7

<212> PRT

<213> human

<220>

<221> DOMAIN

<222> (1) .. (7)

<223> immunodominant motif of the epithelial mucin (
MUC1)

<400> 6

Pro Asp Thr Arg Pro Ala Pro

1

5



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

0051651-000005

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/606,910

06/29/2000

Uwe Karsten

050185

7839

23464 7590 05/01/2007
BUCHANAN INGERSOLL & ROONEY
P.O. BOX 1404
ALEXANDRIA, VA 22313-1404



URGENT

EXAMINER

RAWLINGS, STEPHEN L

ART UNIT	PAPER NUMBER
----------	--------------

1643


MAIL DATE	DELIVERY MODE
-----------	---------------

05/01/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



650185 -
OAS/KMR
Sequence Listing
Due 5/31/07



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---------------------------------------------------	---------------------



EXAMINER

ART UNIT	PAPER
----------	-------

20070425

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen L. Rawlings, Ph.D. whose telephone number is (571) 272-0836. The examiner can normally be reached on Monday-Friday, 8:30AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, Ph.D. can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


STEPHEN L. RAWLINGS, PH.D.
PRIMARY EXAMINER